AREXVY, poudre et suspension pour suspension injectable. Vaccin du Virus Respiratoire Syncytial (VRS) (recombinant, avec adjuvant)

poudre et suspension pour suspension injectable · intramusculaire

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formpoudre et suspension pour suspension injectable

Routeintramusculaire

Ingredient entries1

CountryFrance

Product identity

At a glance

Authorisation holder: GLAXOSMITHKLINE BIOLOGICALS
Authorisation status: Autorisation active
Market status: Commercialisée
Country: France
Source reference: CIS 64431629

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for AREXVY, poudre et suspension pour suspension injectable. Vaccin du Virus Respiratoire Syncytial (VRS) (recombinant, avec adjuvant)
Ingredient	Strength / reference	Source role
GLYCOPROTÉINE F RECOMBINANTE DU VIRUS RESPIRATOIRE SYNCYTIAL STABILISÉE EN FORME PRÉ-FUSION poudre	120 microgrammesune dose de 0,5 mL	SAGroup 1

Pack references

Presentations (1)

1 flacon en verre de 120 microgrammes de poudre - 1 flacon en verre de 0,5 ml de suspension

CIP13 3400930274170

Présentation active · Déclaration de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 64431629 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source file	Retrieved	Source file modified
fr_products.txt	2026-09-17	Not supplied
fr_composition.txt	2026-09-17	Not supplied
fr_packs.txt	2026-09-17	Not supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →